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Background: This study was designed to compare the long-term surgical outcomes of patients with mid and low
rectal cancer after open or hand-assisted laparoscopic surgery (HALS).
Methods: A case-matched controlled prospective analysis of 116 patients who underwent hand-assisted laparoscopic
surgery (HALS) for stage I to III mid and low rectal cancer from 2005 to 2010 was performed. Contemporary patients
who underwent open rectal surgery were matched to the HALS group at the ratio of 1:1. The perioperative clinical
outcomes, postoperative pathology, and survival outcomes were compared between the groups.
Results: The patient characteristics between the two groups were comparable. Ninety patients in the open group and
85 in the HALS group received sphincter-preserving surgery. HALS resulted in less blood loss and wound infection,
faster return to oral diet, shorter postoperative hospital stay, and longer operating time. The two groups had similar
complication rates. Lymph node retrieval and involvement of circumferential and distal margins were similar for both
procedures. Cumulative incidences of locoregional recurrence, disease-free, or overall survival rates were statistically
similar.
Conclusions: This study suggests that HALS for mid and low rectal cancer is acceptable in terms of short-term clinical
outcomes and long-term survival results.
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Recent findings have shown that laparoscopic-assisted
proctectomy (LAP) has equivalent survival outcomes
compared with open resection for mid and low rectal
cancer [1–6]. However, LAP or robotic surgery [7] is
limited by the technical difficulties and long steep learning
curve, especially in obese patients. Whereas hand-assisted
laparoscopic surgery (HALS), a hybrid endoscopic tech-
nique incorporating elements of both laparoscopic and
open techniques, can overcome these existing limitations.* Correspondence: 2810941796@qq.com
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strated more efficient than standard laparoscopic surgery
as far as operating time and conversion rate were con-
cerned [9–13], with oncological clearance comparable to
open colorectal resection [14, 15]. However, to date, little
solid evidence exists in support of HALS for mid and low
rectal cancer in terms of locoregional recurrence and
long-term survival outcomes. Thus, a comparison of
HALS versus the open approach for mid and low rectal
cancer was performed with long-term follow-up.Methods
Between February 2005 and October 2010, consenting
patients who underwent HALS for the treatment of mid
and low rectal adenocarcinoma (≤12 cm from the analicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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was matched against a contemporary open resection
series with mid and low rectal adenocarcinoma (≤12 cm
from the anal verge) that declined to undergo HALS or
LAP at the ratio 1:1 by clinical stage, tumor location,
neoadjuvant therapy, gender, age, and body mass index
(BMI). Patients with tumor infiltration to the adjacent
organs or structures (T4), those with multiple primary
colorectal carcinomas, those with familial adenomatous
polyposis, those with concurrent distant metastases,
those with other malignant diseases, those with recur-
rent rectal cancer, or those with intestinal obstruction
were excluded. This study was approved by the ethics
committee of the First Affiliated Hospital, College of
Medicine, Zhejiang University.
All patients underwent a physical examination, total
colonoscopy plus biopsy. The anesthetist assessed all pa-
tients before the operation and assigned an American
Society of Anesthesiologists (ASA) grade. Thoracic and
abdominal computed tomography (CT) and pelvic mag-
netic imaging or transrectal ultrasound were performed
for preoperative clinical staging. All patients received the
same postoperative treatment protocols, including pain
control, nutrition support, postoperative rehydration,
early ambulation, and early feeding. The discharge cri-
teria included self-feeding, free ambulation, and only
mild pain in the wounds.
Patients with low (0–5 cm) rectal cancers were
suggested to receive neoadjuvant chemoradiation if
the preoperative TNM stage was stage II or III. Other
rectal cancers (5.1–12 cm) were considered selectively
based on the extent of the disease. The regimen
of neoadjuvant chemoradiotherapy was as follows:
4500 cGy in 25 fractions to the pelvis in 5 weeks and a
540 cGy boost in three fractions to the primary tumor,
with oral capecitabine concurrently at a dose of 1000–
1500 mg/m2 per day. The operation was carried out
6–8 weeks after the completion of neoadjuvant treat-
ment by the same surgical team. Postoperative
patients with stage III disease received adjuvant
chemotherapy.
Surgical techniques
Seven surgeons (JJL, JHX, WBC, XMX, FLL, XLZ, CZL)
performed the operations in the department of Colorec-
tal Surgery at the First Affiliated Hospital of Zhejiang
University in the study. Three surgeons (XMX, JJL,
WBC) performed the HALS procedures in the study. All
three surgeons have extensive laparoscopic experience
(>50 hand-assisted laparoscopic colorectal dissections
for benign or malignant diseases).
All patients underwent mechanical bowel preparation.
All patients underwent total mesorectal excision (TME)
with preservation of the hypogastric nerves. For anteriorresection, stapled colorectal or handsewn coloanal anas-
tomoses were constructed. An ileostomy was fashioned
at the surgeon’s discretion, mainly in patients who had
undergone neoadjuvant treatment. The loop ileostomy
was reversed with stapled anastomosis technique or
hand-suture technique when the stapled anastomosis
was not feasible 3 months after the curative surgery. An
abdominoperineal excision (APE) was performed when
it was not possible to obtain a distal margin of more
than 1 cm. Some patients aged >75 years with comorbid-
ities (diabetes, metabolic disorders, anemia) received
Hartmann procedure.
Patients who underwent HALS were placed in the
Lloyd-Davis position with forced Trendelenburg (30°).
The surgeon, utilizing the left hand for retraction and
dissection, stood to the patient’s right, whereas the first
assistant between the patient’s legs. The monitor was
placed on the left side of the patient. HALS was started
with a small straight abdominal incision in the midline
around the umbilicus to place the hand port (Lap-Disc;
Ethicon, Guaynabo, Puerto Rico), which was used for
the removal of the resected specimen. A pneumoperito-
neum was created with a pressure of 12–15 mmHg, and
two additional trocars were placed: a 10-mm trocar in
the suprapubic region for the laparoscope and a 12-mm
working port in the lower right quadrant. The using of a
third 5-mm trocar in the left was at the surgeon’s discre-
tion. Ligation of lymphovascular pedicles and mobilization
of the colon and/or rectum was performed intracorpore-
ally along the “Holy plane” down to the pelvic floor. The
hypogastric nerves, the pelvic parasympathetic plexus, and
the ureters were carefully safeguarded. The lower rectum
was transected with endoscopic linear stapler introduced
through the right lower quadrant port. Intracorporeal
double-stapled colorectal anastomosis technique or hand-
suture coloanal anatomosis were performed tans-anally.
The splenic flexure was mobilized if extra bowel length
was needed to facilitate the construction of a tension-free
anastomosis.
The open group followed the same oncologic princi-
ples as the HALS procedures with a median incision
from the symphysis pubis to the navel. Intestinal separ-
ation was conducted according to TME principle as in
the HALS group.
All specimens were analyzed by experienced patholo-
gists, who assessed harvested lymph nodes, the distal mar-
gin involvement (tumor reaching the distal section), and
the circumferential margin involvement (a distance of
1 mm or less from the tumor to the mesorectal fascia).
The sex, age, height, weight, ASA grade, tumor loca-
tion, and preoperative TNM stage of the patients were
recorded, as were operating time, incision length, blood
loss, postoperative bowel function, complications, anal-
gesic requirements, length of postoperative stay, and
Table 1 Patient characteristics
Open HALS P
value(n = 116) (n = 116)
Sex ratio (M/F) 71/45 68/48 0.688a
Age (years) 64 ± 11 61 ± 16 0.310a
Body mass index (kg/m2) 24.1 ± 5.0 23.3 ± 3.1 0.315a
ASA grade 0.652
I 42 (36.2) 39 (33.6)
II 36 (31.0) 45 (38.8)
III 33 (28.5) 28 (24.1)
IV 5 (4.3) 4 (3.5)
Tumor distance from AV (cm) 0.311a
0–5 cm 37 (31.9) 30 (25.9)
5.1–12 cm 79 (68.1) 86 (74.1)
Preoperative staging 0.861a
I 32 (24.1) 30 (25.9)
II 41 (31.9) 45 (38.8)
III 43 (33.6) 41 (35.3)
Neoadjuvant CRT 33(28.4) 28 (24.1) 0.456
ASA American Society of Anesthesiologists, AV Anal verge,
CRT chemoradiotherapy
aMatched parameters
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cations were recorded using either medical records or by
follow-up.
Symptoms of anastomotic leakage were evaluated by
digital examination (DE) and proctoscopy followed by
abdominal CT scan. Clinical anastomotic leakage was
determined by peritonitis, pelvic abscess, abdominal
drain discharge of feces or pus, discharge of pus from
the rectum, or rectovaginal fistula. CT-enema was per-
formed for suspected patients postoperatively if the
anastomotic dehiscence was not detectable by DE.
Locoregional recurrence was defined as reappearance
of a tumor in the surgical pelvic field. Locoregional re-
currence was confirmed by histological examination.
Distant metastases were diagnosed by radiological and/
or histological examination. Further treatments of resec-
tion or percutaneous radiofrequency ablation were at the
multidisciplinary team’s discretion.
Follow-up
Patients were followed up as outpatients every 3 months
within the first 2 years, every 6 months for the next
3 years subsequently, and at 6 months or yearly there-
after. At each visit, they received a physical examination
and general blood tests. Every 6 months, they alternated
between thoracic and abdominal CT or abdominal ultra-
sonography and chest radiography. A complete colonos-
copy was performed at the 1-year visit.
Statistical analyses
All data were analyzed by the software package Graph-
Pad Prism 6.02 (GraphPad Software, San Diego, CA,
USA) on an intention-to-treat basis. Pearson’s χ2-test (or
Fisher’s exact test when appropriate) and Mann–-
Whitney U test were performed to compare categorical
and numerical data, respectively. Each test was two-
tailed, and P values < 0.05 were considered to be signifi-
cant. The data are expressed as the means ± standard
deviations or numbers with percentages in parentheses
unless otherwise indicated.
Survival rates were calculated with the Kaplan–Meier
estimation method. Survival curves were compared with
the log rank test. For the calculation of disease-free sur-
vival (DFS), patients who died without disease recur-
rence or metastases were censored at the time of death.
Results
One hundred and sixteen patients who underwent HALS
were compared with 116 patients who underwent open
rectal resection. The two groups had comparable demo-
graphic data (Table 1). The operative results are summa-
rized in Table 2. The rate of sphincter-preserving surgery
was similar in the two groups (P = 0.502). Defunctioning
ileostomy was created in 54.9 % of patients whounderwent sphincter-preserving surgery, again with no
differences between groups (P = 0.471). The morbidity
after the closure of loop ileostomy was comparable be-
tween groups. Blood loss and wound infection were sig-
nificantly less in HALS group (P < 0.001 and P = 0.015,
respectively). Mean operating time was 34 min longer for
HALS than open surgery (P < 0.001). Return to oral diet
and postoperative hospital stay were longer in the open
group (P < 0.001). The rates of anastomotic dehiscence,
which occurred in eight (8.9 %) patients in the open group
and seven (8.2 %) in HALS group, did not differ signifi-
cantly (P = 0.877). There was one death (0.9 %) in the
open group due to respiratory infection and multiple
organ failure. One death in the HALS group was due to
anastomotic dehiscence and subsequent septic shock.
There was a similar incidence between the open and
HALS groups with respect to chest infection, urinary re-
tention, rectovaginal fistula, urinary fistula, incision her-
nia, and parastomal hernia. One operation (0.9 %) in the
HALS group was converted to an open procedure. The
patient with distal margin involved received a salvage sur-
gery of APE.
Pathological examination data of the specimen were
listed in Table 3. Involvement of the circumferential
margin and distal margin and the number of isolated
lymph nodes were not significantly different between the
2 groups. In the open group for patients with CRM in-
volved, five had locoregional recurrences and three
Table 2 Operative data and postoperative complications
Open HALS P value
(n = 116) (n = 116)
Surgical procedure 0.502
Dixon 90 (77.6) 85 (73.2)
Hartmann 12 (10.3) 18 (15.5)
APE 14(12.1) 13 (11.2)
Anastomosisb 0.758
Stapled 82 (90.2) 80 (94.1)
Handsewn 8 (9.8) 5 (5.9)
Loop ileostomyb 47 (52.2) 49 (57.6) 0.471
Morbidity of loop ileostomy closure 10 (21.3) 9 (18.4) 0.721
Incision length (cm) 16 ± 2 6 ± 1 <0.001
Operative time (minutes) 126 ± 21 160 ± 36 <0.001
Blood loss (ml) 392 ± 95 262 ± 136 <0.001
Duration of narcotic analgesia(days) 3.2 ± 1.2 2.0 ± 1.1 <0.001
Return to oral diet (days) 4.3 ± 1.6 2.9 ± 1.5 <0.001
Length of postoperative stay (days) 8.5 ± 2.5 6.5 ± 2.0 <0.001
Complications 36 (31.0) 31(26.7) 0.469
Anastomotic leakageb 8 (8.9) 7 (8.2) 0.877
Anastomotic bleedingb 5 (5.6) 3 (3.5) 0.721a
Rectovaginal fistulab 2 (2.2) 2 (2.4) 1.000a
Wound infectionc 15 (12.9) 4 (3.4) 0 · 015a
Chest infectionc 7 (6.0) 3 (2.6) 0 · 333a
Urinary fistulac 0 (0) 2 (1.7) 0.498a
Urinary retentionc 9 (7.8) 6 (5.2) 0.423
Intestinal obstructionc 6 (5.2) 11 (9.5) 0.208
Incision herniac 4 (3.4) 1 (0.9) 0 · 370a
Parastomal herniac 2 (1.7) 2 (1.7) 1.000a
Postoperative deathc 1 (0.9) 1 (0.9) 1.000a
Conversion to open surgery 1
APE Abdominoperineal excision
aFisher Exact test
bCalculated from the operation of Dixon
cCalculated from the curative surgery
Table 3 Pathological characteristics after curative resection
Open HALS P value
(n = 116) (n = 116)
Pathological TNM stage 0.711b
CR 1 (0.9) 1 (0.9)
0 2 (1.7) 1 (0.9)
I 30 (25.9) 27 (23.3)
II 46 (39.6) 52 (44.8)
III 37 (31.9) 35 (30.2)
T stage 0.641c
T0 1 (0.9) 1 (0.9)
Tis 2 (1.7) 1 (0.9)
T1 11 (9.5) 17 (14.6)
T2 31 (26.7) 29 (25)
T3 71 (61.2) 68 (58.6)
N stage 0.578
N0 79 (68.1) 81 (69.8)
N1 17 (14.7) 12 (10.4)
N2 20 (13.8) 23 (12.9)
Grade of differentiation 0.687
Well 12 (10.3) 18 (15.5)
Moderate 80 (69.0) 75 (64.7)
Poor 17 (1.7) 16 (13.8)
Mucinous 5 (4.3) 6 (5.2)
Unknown 2 1
Isolated lymph nodes 12.2 ± 3.5 13.5 ± 4.6 0.342
CRM 0.374a
Involved (≤1 mm) 8 (5.4) 4 (3.4)
Noninvolved (>1 mm) 99 (85.3) 101 (87.1)
Missing 9 11
Distal margin involvedc 0 (0) 1 (1.0) 1.000a
CR Complete response, CRM Circumferential resection margin
aFisher exact test
bCR, TNM stage 0, and stage I were combined for statistical analysis
cT0, Tis, and T1 were combined for statistical analysis
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the four patients with CRM involved developed both
locoregional and distal recurrences.
The duration of follow-up was 63.3 ± 23.4 months for
the open group and 61.5 ± 21.9 months for the HALS
group (P = 0.516). Locoregional recurrence was similar
between groups (P = 0.814) (Fig. 1). There were no inci-
sion or port sites recurrences. Nineteen patients in the
open group and twenty-two patients in the HALS group
developed distal metastases. The overall 5-year survival
rate was 80.4 % in the open group and 82.6 % in the
HALS group (P = 0.617) (Fig. 2a). The subgroup survival
analysis according to the stage was similar between both
groups (Fig. 2b–d). The 5-year DFS rate was 76.4 % inthe open group and 74.4 % in the HALS group (P =
0.832) (Fig. 3a), with a subgroup analysis similar, too
(Fig. 3b–d).
Discussion
This study suggested that HALS was associated with less
blood loss, faster gastrointestinal recovery, and shorter
postoperative hospital stay, without compromise of onco-
logical clearance compared with open laparotomy for mid
and low rectal cancer. Notably, the rates of locoregional
recurrence, DFS and OS were similar between the two
groups through long-term follow-up.
The potential advantages of HALS have been delin-
eated previously in colorectal surgery [14, 16–20]. The
Fig. 1 Locoregional recurrence in Open and HALS groups
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benefits of minimally invasive surgery and may allow the
surgeon to carry out complicated procedures efficiently
[18]. Surgeons can easily locate tumors by tactile feed-
back and decrease iatrogenic injuries. Moreover, the sur-
geon’s left hand inside the abdomen greatly facilitates
the placement of the linear stapler and the mobilization
of the left colon [21]. Not surprisingly, as a consequence,
HALS group resulted in shorter operating time and
comparable lengths of hospitalization stay compared
with LAP although the incision of HALS was a little bit
longer [12]. Furthermore HALS resulted in low conver-
sion rate being varied from 0 to 10 % [15], which was
consistent with our data. nevertheless, in published LAP
series, the conversion rate to open surgery varied from
1.2 to 29 % (1.2 % in the COREAN trial [4], 7.5 % in
Ng’s study [2], 7.9 % in Lujan’s study [3], 17 % in the
COLOR II trial [22], and 29 % in the CLASICC trial
[23]). What is particularly worth mentioning is that the
conversion rate of LAP increased with increasing BMI
[24]. For obese patients (BMI > 30) the conversion rate
could reach as high as 31.9 % [24]. Whereas, in a study
carried out in Cleveland Clinic in obese patients (BMI >
30), HALS resulted in lower conversion rate compared
with LAP (3.5 vs. 12.7 %). Therefore, Heneghan et al.
suggested HALS as a first-line approach for colorectal
surgery in obese patients [9]. It also indicated that con-
version from LAP to HALS in difficult or complicated
cases should be considered to reduce conversion rate to
open surgery.
However, HALS port placement and trocar arrange-
ment varies with different surgeons [16–20]. Someauthors [17] preferred to place the Gelport in the low
midline or Pfannenstiel incision. Our experience showed
that midline HALS port placement around the umbilicus
greatly facilitated four-quadrant dissection, especially
when the splenic flexure mobilization was required. The
surgeon’s hand in the abdomen greatly facilitates retrac-
tion, dissection, and hemostasis. If inappropriate, how-
ever, the hand might be cumbersome rather than
helpful. In addition to appropriate positioning of the
HALS port, correct trocar placement is of vital import-
ance. The principles of instrument triangulation should
be adhered to in trocar arrangements. The laparoscope
port site may be better when placed in the midline in
the suprapubic region allowing views of the entire pelvic
area and the whole rectum by adjusting the 30° lens of
the laparoscope, for otherwise, the hand is unable to be
helpful and can become a hindrance. Under this proto-
col, the left side trocar was rarely needed in addition to
the working port at the right side.
It is worthy to be noted that HALS surgery cannot de-
crease the anastomotic leakage rate. Defunctioning ileos-
tomy was required to mitigate the serious sequelae of an
anastomotic leak. However, the morbidity after loop ile-
ostomy closure remains high. More recently, tube ileos-
tomy has been performed to avoid the construction of
loop ileostomy, and the preliminary results were promis-
ing [25–27].
Previous studies and meta-analyses have shown that
laparoscopic TME was an oncologically correct tech-
nique. The rate of distal and circumferential margin in-
volvement and the number of isolated lymph nodes
were reported similar for both laparoscopic and open
techniques [28–30]. Nevertheless, data on the number of
harvested lymph nodes, positive margin rate, and recur-
rence rate were seldom reported in HALS study. The
pathological data in our study suggested that HALS was
oncologically acceptable in the mid and low rectal can-
cer surgery.
Despite the short-term benefits, the long-term survival
outcome of HALS for mid and low rectal cancer was
rarely reported, which, however, is mandatory for estab-
lishing the value of HALS in the surgical treatment. The
short-term benefits of HALS should not be compro-
mised by the incidence of locoregional recurrence and
survival. There were discrepancies between LAP and
open surgery group for rectal cancer in terms of survival
outcomes. In the CLASICC trial, the 5-year OS rates for
the rectal cancer patients were not statistically different
between the LAP (60.3 %) and open (52.9 %) groups
[1]. In the COREAN trial, LAP group provides similar
outcomes of three-year DFS as open surgery for locally
advanced rectal cancer after preoperative chemoradio-
therapy [4]. Lujan et al. [3] reported similar results.
These results were in line with our findings. Ng et al.
Fig. 2 Overall survival rate of patients with HALS or Open surgery ((a) all stages; (b) stage 0-I; (c) stage II; (d) stage III)
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tage over the open approach. However, its small sample
size did not allow convincing conclusion to be drawn.
We must note, however, that HALS technique has lim-
itations. First of all, HALS requires additional use of
hand port, which increases the surgical cost and may re-
sult in fatigue and numbness of the surgeon’s hand in
some cases, though some reported that the overall cost
was equivalent [31]. Additionally, HALS resulted in lon-
ger operative duration, which may be partly owing to the
complexity of rectal surgery. The increased handling and
mobilization of the bowel was speculated to result in the
development of postoperative ileus and intra-abdominal
adhesions, whereas in our study, the increased duration
is unlikely to cause negative impacts on patientsclinically. Moreover, the study was limited by the ab-
sence of data concerning genitourinary functional out-
comes and non-randomization design. Future well-
designed multicenter studies with more patients are
needed to allow a more convincing evaluation, and fur-
ther comparative study to evaluate HALS vs. LAP for
mid and low rectal cancer, especially in obese patients, is
also required.
Conclusions
In conclusion, surgeons now have many different op-
tions to achieve a minimally invasive operation for colo-
rectal resection, and our data suggests that HALS for
mid and low rectal cancer can improve postoperative re-
covery, reduces blood loss and postoperative hospital
Fig. 3 Disease-free survival rate of patients with HALS or Open surgery ((a) all stages; (b) stage 0-I; (c) stage II; (d) stage III)
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compared with open laparotomy.
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